Pharmacokinetics of New Antiepileptic Drugs
- 1 December 1996
- Vol. 37 (s6) , S12-S16
- https://doi.org/10.1111/j.1528-1157.1996.tb06034.x
Abstract
This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin. Compared to the pharmacokinetics of standard AEDs, these new AEDs have progressed in terms of (a) longer half-lives, permitting once- or twice-daily dosing, (b) greatly reduced potential for drug interactions, thus increasing ease of treatment, and (c) general lack of hepatic enzyme induction, which facilitates polytherapy as well as other aspects of treatment.Keywords
This publication has 39 references indexed in Scilit:
- The Place of Felbamate in the Treatment of EpilepsyCNS Drugs, 1995
- Felbamate in the Treatment of Lennox‐Gastaut SyndromeEpilepsia, 1994
- Drug Interactions With Antiepileptic AgentsCNS Drugs, 1994
- The Clinical Pharmacology of the New Antiepileptic DrugsPharmacological Research, 1993
- FelbamateDrugs, 1993
- Comparative Pharmacokinetics of the Newer Antiepileptic DrugsClinical Pharmacokinetics, 1993
- Possible Interaction Between Oxcarbazepine and an Oral ContraceptiveEpilepsia, 1992
- Absence of interaction between oxcarbazepine and erythromycinActa Neurologica Scandinavica, 1992
- Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11 -epoxideEpilepsy Research, 1992
- Pharmacokinetics and safety of lamotrigine (Lamictal®) in patients with epilepsyPublished by Elsevier ,1991